|
1
|
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
|
Proc Natl Acad Sci U S A
|
2004
|
2.58
|
|
2
|
The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.
|
Blood
|
2002
|
2.25
|
|
3
|
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.
|
Proc Natl Acad Sci U S A
|
2007
|
1.99
|
|
4
|
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
|
Proc Natl Acad Sci U S A
|
2010
|
1.84
|
|
5
|
Immunohistochemical detection of WT1 protein in a variety of cancer cells.
|
Mod Pathol
|
2006
|
1.62
|
|
6
|
AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
|
Blood
|
2005
|
1.26
|
|
7
|
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
|
Int J Hematol
|
2003
|
1.18
|
|
8
|
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
|
J Neurosurg
|
2008
|
1.16
|
|
9
|
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
|
Cancer Immunol Immunother
|
2002
|
1.08
|
|
10
|
Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle.
|
Int J Oncol
|
2009
|
1.08
|
|
11
|
WT1 peptide vaccine for the treatment of cancer.
|
Curr Opin Immunol
|
2008
|
1.04
|
|
12
|
Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors.
|
Int J Oncol
|
2008
|
1.04
|
|
13
|
Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.
|
Br J Haematol
|
2002
|
1.02
|
|
14
|
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.
|
Blood
|
2002
|
0.98
|
|
15
|
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
|
Jpn J Clin Oncol
|
2006
|
0.98
|
|
16
|
Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
|
J Immunother
|
2014
|
0.95
|
|
17
|
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
|
Microbiol Immunol
|
2007
|
0.95
|
|
18
|
Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas.
|
Cancer Sci
|
2003
|
0.94
|
|
19
|
Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro.
|
Cancer Sci
|
2006
|
0.91
|
|
20
|
WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
|
ScientificWorldJournal
|
2007
|
0.91
|
|
21
|
WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
|
Microbiol Immunol
|
2004
|
0.90
|
|
22
|
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
|
Int J Hematol
|
2007
|
0.89
|
|
23
|
CD48 as a novel molecular target for antibody therapy in multiple myeloma.
|
Br J Haematol
|
2011
|
0.89
|
|
24
|
Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
|
J Neurosurg
|
2012
|
0.88
|
|
25
|
Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma.
|
Cancer
|
2006
|
0.88
|
|
26
|
High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ.
|
Cancer Sci
|
2009
|
0.86
|
|
27
|
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
|
J Immunother
|
2007
|
0.85
|
|
28
|
Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
|
Cancer Sci
|
2009
|
0.84
|
|
29
|
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
|
Jpn J Clin Oncol
|
2010
|
0.84
|
|
30
|
WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.
|
Anticancer Res
|
2012
|
0.83
|
|
31
|
Low Wilms' tumor gene expression in tumor tissues predicts poor prognosis in patients with non-small-cell lung cancer.
|
Cancer Invest
|
2011
|
0.83
|
|
32
|
The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
|
Transpl Immunol
|
2003
|
0.83
|
|
33
|
WT1 peptide vaccination for the treatment of hematological malignancies: the present status and future direction.
|
Rinsho Ketsueki
|
2009
|
0.82
|
|
34
|
The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.
|
Int J Hematol
|
2003
|
0.82
|
|
35
|
The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver.
|
Biochem Biophys Res Commun
|
2005
|
0.81
|
|
36
|
Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.
|
Int J Hematol
|
2007
|
0.81
|
|
37
|
WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
|
Cancer Immunol Immunother
|
2004
|
0.81
|
|
38
|
WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.
|
J Cancer Res Clin Oncol
|
2012
|
0.81
|
|
39
|
WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
|
Pediatr Hematol Oncol
|
2009
|
0.81
|
|
40
|
Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
|
Vaccine
|
2011
|
0.81
|
|
41
|
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
|
Cancer Immunol Immunother
|
2015
|
0.80
|
|
42
|
"Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.
|
Curr Med Chem
|
2008
|
0.80
|
|
43
|
WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.
|
Cell Physiol Biochem
|
2015
|
0.80
|
|
44
|
The role of WT1 gene in neuroblastoma.
|
J Pediatr Surg
|
2011
|
0.80
|
|
45
|
Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
|
Microbiol Immunol
|
2008
|
0.80
|
|
46
|
A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.
|
Microbiol Immunol
|
2008
|
0.79
|
|
47
|
Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.
|
Leuk Res
|
2010
|
0.79
|
|
48
|
Vaccination with WT-1 (Wilms' tumor gene-1) peptide and BCG-CWS in melanoma.
|
Eur J Dermatol
|
2012
|
0.78
|
|
49
|
Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients.
|
Brain Tumor Pathol
|
2010
|
0.78
|
|
50
|
Sensitive immunohistochemical detection of WT1 protein in tumors with anti-WT1 antibody against WT1 235 peptide.
|
Cancer Sci
|
2010
|
0.78
|
|
51
|
Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.
|
Cancer Med
|
2014
|
0.77
|
|
52
|
WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
|
Anticancer Agents Med Chem
|
2009
|
0.77
|
|
53
|
A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
|
Anticancer Res
|
2010
|
0.77
|
|
54
|
Expression of Wilms tumor 1 gene in a variety of pediatric tumors.
|
J Pediatr Surg
|
2011
|
0.77
|
|
55
|
HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
|
J Immunother
|
2013
|
0.77
|
|
56
|
Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
|
Int J Hematol
|
2003
|
0.77
|
|
57
|
Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
|
Anticancer Res
|
2012
|
0.76
|
|
58
|
Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.
|
Cancer Sci
|
2012
|
0.76
|
|
59
|
Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.
|
Expert Rev Hematol
|
2014
|
0.76
|
|
60
|
Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis.
|
Anticancer Res
|
2014
|
0.76
|
|
61
|
Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
|
Transplantation
|
2002
|
0.76
|
|
62
|
Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
|
Cancer Immunol Immunother
|
2015
|
0.76
|
|
63
|
WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.
|
Int J Hematol
|
2005
|
0.75
|
|
64
|
[III. Peptide vaccination therapy against brain tumors].
|
Gan To Kagaku Ryoho
|
2015
|
0.75
|
|
65
|
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
|
Oncol Res Treat
|
2017
|
0.75
|
|
66
|
An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
|
J Immunother
|
2016
|
0.75
|
|
67
|
[Cellular and humoral immune responses against WT1 products overexpressed in hematopoietic malignancies].
|
Rinsho Ketsueki
|
2002
|
0.75
|
|
68
|
Functional human Th17 clones with WT1-specific helper activity.
|
Cancer Immunol Immunother
|
2012
|
0.75
|
|
69
|
[WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms].
|
Rinsho Ketsueki
|
2011
|
0.75
|
|
70
|
Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation.
|
Transplantation
|
2004
|
0.75
|
|
71
|
Primary lung involvement with amyloid deposition in Waldenstöm's macroglobulinemia: observations from over 20 years.
|
Respirology
|
2004
|
0.75
|